State coverage
Alaska Medicaid and GLP-1 coverage
Medicaid, for obesity: Does not cover. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- The pharmacy manual excludes obesity drugs by name; the statewide drug list carries GLP-1s for diabetes only.
Alaska is one of the more direct answers on this site because the exclusion is written into the pharmacy manual itself, not left for a reader to infer from a drug list's silence. The manual's non-covered services section names obesity medications alongside infertility and baldness drugs — the same sentence structure a lot of states use for a small, deliberately excluded category.
The state's Preferred Drug List backs that up from a different angle. It carries a full "Hypoglycemics, Incretin Mimetics/Enhancers" class with Ozempic, Rybelsus, Victoza and Mounjaro all listed for diabetes — but nowhere across the document's several hundred drug-class entries does Wegovy, Zepbound or Saxenda appear, under any name or status. We also checked the state's Prior Authorization Medication List and its PA-criteria index page directly, reading the live page text rather than just its file names; neither carries an obesity, weight-loss or GLP-1 entry either. Three separate documents, read on the same day, agree with each other.
What we could verify for Alaska
The manual states the exclusion directly, in a short list next to two other narrow exclusions. Under "Non-covered Pharmacy Services," it reads: "The services listed below are non-covered pharmacy services... Medications used to treat infertility, obesity, or baldness."
Alaska Department of Health, Alaska Medicaid Pharmacy Provider Manual (Pharmacy Services, Policies, and Procedures), effective November 2023 · source
The statewide drug list confirms the exclusion by omission across its entire diabetes class. Under "HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS," the list carries OZEMPIC (PEN), OZEMPIC (SUBCUTANE.), RYBELSUS (ORAL), VICTOZA (SUBCUTANE.), LIRAGLUTIDE and MOUNJARO (SUBCUTANE.), each with a PDL status effective date of 11/1/2025 — but no line for WEGOVY, WEGOVY HD, ZEPBOUND or SAXENDA appears anywhere in the document, posted 04/30/2026 for an effective date of 06/01/2026.
Alaska Department of Health, Alaska Medicaid Preferred Drug List (PDL), effective June 2026 · source
The recipient handbook describes how to ask for a fair hearing but does not itself state a filing deadline: "A Fair Hearing is a chance for you to tell an administrative law judge why you think that the Department of Health is incorrect... A fair hearing request can be submitted by telephone or via text, email, USPS mail, or by fax," addressed to "Alaska Medicaid Fiscal Agent, Attention: Fair Hearings, PO Box 240808, Anchorage, AK 99524."
State of Alaska, Department of Health, Alaska Medicaid Recipient Handbook, effective April 2025 · source
The deadline the handbook omits is set in regulation: "a request for a hearing within the scope of 7 AAC 49.020 must be made to the department in writing by a recipient, or by a legal representative acting on the recipient's behalf, not later than 30 days after the date of the notice required under 7 AAC 49.060."
Alaska Administrative Code, 7 AAC 49.030 (Request for hearing) · source
Alaska is one of 6 states whose Medicaid gives the same answer: weight loss excluded, and no other route named. Alaska Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare Alaska with the rest in the coverage matrix.
Regional insurers that sell plans in Alaska and have their own page here, quoted from their own policy documents: Premera Blue Cross. The national insurers are on the insurance index.
If you work for the State of Alaska
State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: AlaskaCare Employee Health Plan. Its pharmacy benefit runs through Optum Rx.
Covered with PA; Virta prescriber required
AlaskaCare's employee plan covers Wegovy, Zepbound and Saxenda as preferred brands with prior authorization. Since January 2026, a weight-loss GLP-1 prescription has to come from a Virta provider, through a program run with Optum Rx.
"Effective January 1, 2026, the AlaskaCare Employee Health Plan is implementing a weight loss program managed by Virta in conjunction with Optum Rx for all members with a weight loss Glucagon-Like Peptide-1 (GLP-1) prescription."
Alaska Division of Retirement and Benefits, AlaskaCare Employee Health Plans, effective January 2026 · source
"Beginning in 2026, you will only be able to fill a GLP-1 prescription for weight loss that has been prescribed by a Virta provider."
Alaska Division of Retirement and Benefits, AlaskaCare Employee Health Plans, effective January 2026 · source
"Which GLP-1 medications are included in this change? Wegovy, Zepbound, Saxenda, and the generic GLP-1, liraglutide." "Members who use GLP-1 to manage diabetes or other conditions will not be affected."
Alaska Division of Retirement and Benefits, AlaskaCare Employee Health Plans, effective January 2026 · source
The 2026 formulary lists Wegovy and Zepbound on tier 3 with "PA; QL (0.08 ML per 1 day)" for the starting Wegovy doses and Zepbound. Tier 3 is the preferred-brand tier: "Use tier 3 drugs instead of tier 4 to help reduce your out-of-pocket costs."
Optum Rx, AlaskaCare Employee Plan Prescription Drug Formulary, Effective Jan. 1, 2026, effective January 2026 · source
If the appeal fails, or you cannot wait
Alaska Medicaid doesn't pay for these drugs for weight loss and names no other route, so if you're covered only by Medicaid here, paying cash may be the only way to get one. That means the whole cost, every month, with nothing counted toward your coverage.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
| Company | What we found on its own site |
|---|---|
| PartnerWillowCheck availability | Compounded semaglutide at $299 a month (weekly injection or daily tablet) and tirzepatide injections at $399. HSA and FSA accepted; a full refund applies only if you cancel before the prescription reaches the pharmacy. |
| PartnerHumeCare+Check availability | A self-pay membership with no price shown before checkout, renewing automatically. The home page promises your money back if you don't lose 10 percent in six months; the terms limit that to 90 days, first-time users and no measurable loss. |
| PartnerEnhance MDCheck availability | Offers compounded semaglutide and tirzepatide with provider consultations and follow-up. Compounded drugs are not FDA-approved; ask which pharmacy will dispense your prescription and what continuing care includes. |
| PartnerCoreAge RxCheck availability | Compounded semaglutide advertised at $99 a month at every dose. The page our link opens has shown $149 instead, and a consultation fee can be added that may not be refundable. |
| PartnerOakCheck availability | One flat price at every dose, with shipping and supplies included free. |
| PartnerGala HealthCheck availability | One price at every dose. The advertised rate needs a yearly subscription. |
All 21 companies, with what we found on each →
Prices in those notes were read from each company's own site in September 2026, October 2026 and August 2026, and they change often. Check the current number before you buy.
Where this comes from
- Alaska Department of Health, Alaska Medicaid Pharmacy Provider Manual (Pharmacy Services, Policies, and Procedures), effective November 2023 — extranet-sp.dhss.alaska.gov/hcs/medicaidalaska/Provider/Manuals/Pharmacy
- Alaska Department of Health, Alaska Medicaid Preferred Drug List (PDL), effective June 2026 — health.alaska.gov/media/dq0ohdan/pdl_effective-date_20260601.pdf
- State of Alaska, Department of Health, Alaska Medicaid Recipient Handbook, effective April 2025 — health.alaska.gov/media/ux4ds44w/ada-compliant-2025-medicaid-recipient-h
- Alaska Administrative Code, 7 AAC 49.030 (Request for hearing) — www.akleg.gov/basis/aac.asp?media=print&secStart=7.49.030&secEnd=7.49.03